|Last Price||Today's Change||52-Week Range||Trading Volume|
|51.84||0.46 (+0.90%)||36.26 - 55.70||1.4 million|
Market data as of 11:21AM 09/16/14. Quotes are delayed by at least 15 min.
OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer
09/16/2014 6:30 AM ET